Director/PDMR Shareholding

AstraZeneca PLC

15 November 2024

 

15 November 2024 14:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that it was notified that Michel Demaré, Non-Executive Chair of the Board, purchased 2,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 15 November 2024, as set out below.

PDMR	Position	Nature of the transaction	Quantity	Price
Michel Demaré	Non-Executive Chair of the Board	Purchase of Ordinary Shares	2,000	GB£100.30

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michel Demaré
2	Reason for the notification
a)	Position/status	Non-Executive Chair of the Board
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c)	Price(s) and volume(s)	Price(s) Volume(s) £100.303520 2,000
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	15 November 2024
f)	Place of the transaction	LON

AstraZeneca 

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END